title: ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð¾Ð´Ð½Ð¾Ð´Ð¾Ð¼ÐµÐ½Ð½ÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ» Ðº ÑÐ²ÑÐ·Ð°Ð½Ð½Ð¾Ð¼Ñ Ð¸ Ð½Ðµ ÑÐ²ÑÐ·Ð°Ð½Ð½Ð¾Ð¼Ñ Ñ Ð¼ÐµÑÐ°Ð»Ð»Ð°Ð¼Ð¸ ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Obtaining recombinant single-domain antibodies to metal-bound and non-metal-bound human transferrin
Creators: name: Ð¡Ð°ÑÐºÐ¾, ÐÐ½Ð°ÑÑÐ°ÑÐ¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÐÐ¸Ð¾ÑÐµÑ Ð½Ð¾Ð»Ð¾Ð³Ð¸Ñ
Ð¾Ð´Ð½Ð¾Ð´Ð¾Ð¼ÐµÐ½Ð½Ð¾Ðµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð¾
Ð½Ð°Ð½Ð¾ÑÐµÐ»Ð¾
Ð°Ð¿Ð¾ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½
Ð³Ð¾Ð»Ð¾ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½
Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐ¾ÑÐ±ÐµÐ½Ñ
Ð°ÑÑÐ¸Ð½Ð½Ð°Ñ Ñ ÑÐ¾Ð¼Ð°ÑÐ¾Ð³ÑÐ°ÑÐ¸Ñ
Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑ
ÑÐ°Ðº ÑÐ¸ÑÐ½Ð¸ÐºÐ°
single-domain antibody
nanobody
apotransferrin
holotransferrin
immunosorbent
affinity chromatography
biomarker
ovarian cancer

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ ÑÐ½Ð¸ÐºÐ°Ð»ÑÐ½ÑÐµ Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐ¾ÑÐ±ÐµÐ½ÑÐ¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð½Ð°Ð½Ð¾ÑÐµÐ» Ð´Ð»Ñ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð·Ð½Ð°ÑÐ¸Ð¼ÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. Ð Ð¿ÑÐ¾ÑÐµÑÑÐµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ ÑÐµÑÐ°Ð»Ð¸ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð·Ð°Ð´Ð°ÑÐ¸: 1. ÐÐ°ÑÐ°Ð±Ð¾ÑÐºÐ° Ð² Ð±Ð°ÐºÑÐµÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð¹ ÑÐ¸ÑÑÐµÐ¼Ðµ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð¸ Ð¾ÑÐ¸ÑÑÐºÐ° ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÑÑÑÐ¸Ñ Ð½Ð°Ð½Ð¾ÑÐµÐ», Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÑ ÑÐ°Ð½ÐµÐµ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð² Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ ÐºÐ¾Ð´Ð¸ÑÑÑÑÐ¸Ðµ Ð¸Ñ ÐºÐ»Ð¾Ð½Ñ ÐºÐÐÐ. 2. ÐÐ½Ð°Ð»Ð¸Ð· ÐºÐ°ÑÐµÑÑÐ²Ð° Ð¸ Ð¾Ð±ÑÐµÐ¼Ð¾Ð² Ð½Ð°ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð±ÐµÐ»ÐºÐ° ÑÐ¾ ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐ½Ð¾ÑÑÑÑ ÑÐ·Ð½Ð°Ð²Ð°Ð½Ð¸Ñ Ð² Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ð¸ ÑÐ²ÑÐ·Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð¸ Ð½Ðµ ÑÐ²ÑÐ·Ð°Ð½Ð½Ð¾Ð³Ð¾ Ñ Ð¼ÐµÑÐ°Ð»Ð»Ð°Ð¼Ð¸ ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½Ð° ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. 3. ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐ¾ÑÐ±ÐµÐ½ÑÐ¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð²ÑÑÐ¾ÐºÐ¾Ð°ÑÑÐ¸Ð½Ð½ÑÑ Ð½Ð°Ð½Ð¾ÑÐµÐ» Ðº Ð´Ð²ÑÐ¼ ÑÐ¾ÑÐ¼Ð°Ð¼ ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½Ð° Ð¸ Ð¸Ñ Ð°Ð½Ð°Ð»Ð¸Ð·. 4. ÐÐ½Ð°Ð»Ð¸Ð· Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐ¾ÑÐ±ÐµÐ½ÑÐ¾Ð² Ð´Ð»Ñ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¸Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ¸Ð¹ Ð¸ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ð¹ Ð² Ð¾ÑÐ½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð¹ Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð°Ð¿Ð¾- Ð¸ Ð³Ð¾Ð»Ð¾ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½Ð° Ð² ÐºÑÐ¾Ð²Ð¸ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. 5. ÐÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐµÐ³Ð¾ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð² Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ð¸ Ð±Ð¾Ð»ÑÐ½ÑÑ ÑÐ°ÐºÐ¾Ð¼ ÑÐ¸ÑÐ½Ð¸ÐºÐ°. Ð¡ÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÑÑ Ð¾Ð±ÑÐ°Ð±Ð¾ÑÐºÑ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½ÑÑ Ð´Ð°Ð½Ð½ÑÑ Ð¾ÑÑÑÐµÑÑÐ²Ð»ÑÐ»Ð¸ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¿Ð°ÐºÐµÑÐ° Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼ Microsoft Office (Access, Excel, Word), Adobe Photoshop, GraphPad. ÐÑÐ¸ Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½Ð¸Ð¸ Ð¾Ð±Ð·Ð¾ÑÐ° Ð»Ð¸ÑÐµÑÐ°ÑÑÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð»Ð¸ Ð±Ð°Ð·Ñ Ð´Ð°Ð½Ð½ÑÑ: PubMed, Elsevier, Scopus, Web of Science, eLIBRARY.RU, ScienceDirect Ð¸ Ð´ÑÑÐ³Ð¸Ðµ. ÐÑÑÐµÐ¼ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾Ð³Ð¾ ÑÐ¾Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ñ holoTf/apoTf Ð² Ð¿Ð»Ð°Ð·Ð¼Ðµ ÐºÑÐ¾Ð²Ð¸ Ð±Ð¾Ð»ÑÐ½ÑÑ ÑÐ°ÐºÐ¾Ð¼ ÑÐ¸ÑÐ½Ð¸ÐºÐ° Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð¿Ð°ÑÐ°Ð»Ð»ÐµÐ»ÑÐ½Ð¾Ðµ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ðµ ÑÐ¾Ð·Ð´Ð°Ð½Ð½ÑÑ Ð½Ð°Ð¼Ð¸ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐ¾ÑÐ±ÐµÐ½ÑÐ¾Ð² Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ Ð²ÑÑÐ²Ð»ÑÑÑ ÑÐ°Ð·Ð»Ð¸ÑÐ¸Ñ Ð¸ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð² Ð¾ÑÐ½Ð¾ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð¹ Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð°Ð¿Ð¾- Ð¸ Ð³Ð¾Ð»Ð¾ÑÑÐ°Ð½ÑÑÐµÑÑÐ¸Ð½Ð° Ð² Ð¿Ð»Ð°Ð·Ð¼Ðµ ÐºÑÐ¾Ð²Ð¸ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, ÑÑÐ¾ Ð¼Ð¾Ð¶ÐµÑ Ð¾ÑÑÐ°Ð¶Ð°ÑÑ ÑÐ¸ÑÐº Ð¸ ÑÑÐµÐ¿ÐµÐ½Ñ ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¿ÑÐ¾ÑÐµÑÑÐ¾Ð² Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¸ ÑÐ»ÑÐ¶Ð¸ÑÑ Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð²ÐµÑÐ¾ÑÑÐ½Ð¾Ð³Ð¾ Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑÐ° ÑÐ°ÐºÐ° ÑÐ¸ÑÐ½Ð¸ÐºÐ¾Ð².
description: This research shows the unique possibilities of using immunosorbents based on nanobodies for the potential diagnosis of significant human diseases. 1. Development in a bacterial expression system and purification of the corresponding nanobodies, using cDNA clones encoding them, previously obtained in the laboratory. 2. Analysis of the quality and volume of protein production with recognition specificity for metal-bound and non-metal-bound human transferrin. 3. Preparation of immunosorbents based on high-affinity nanobodies to two forms of transferrin and their analysis. 4. Analysis of the possibility of using immunosorbents to identify differences and changes in the relative abundance of apo- and holotransferrin in human blood. 5. Conducting diagnostics and subsequent statistical analysis in relation to patients with ovarian cancer. Statistical processing of experimental data was carried out using the Microsoft Office software package (Access, Excel, Word), Adobe Photoshop, GraphPad. When performing the literature review, the following databases were used: PubMed, Elsevier, Scopus, Web of Science, eLIBRARY.RU, ScienceDirect and others. Diagnostics and statistical analysis of the quantitative ratio of holoTf/apoTf in the blood plasma of patients with ovarian cancer were carried out. It was shown that the parallel use of the immunosorbents we created makes it possible to identify differences and changes in the relative abundance of apo- and holotransferrin in human plasma. This may reflect the risk and extent of pathological processes in an individual and serve as a possible biomarker for ovarian cancer.